Day One Biopharmaceuticals Stock Pattern Recognition Advance Block

Stocks . USA . 
Stock . Day One Biopharmaceuticals
DAWN Stock  USD 21.31  0.04  0.19%   
The pattern recognition view organizes Advance Block recognition and supporting indicators around Day One. The focus on pattern recognition signals tied to momentum and continuation helps organize trend, volatility, and risk context for Day One.

Recognition
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was twelve with a total number of output elements of forty-nine. The function did not return any valid pattern recognition events for the selected time horizon. The Advance Block describes upcoming bearish signal for Day One.

Day One Technical Analysis Modules

Most technical analysis of Day One help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Day from various momentum indicators to cycle indicators. When you analyze Day charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.
Cycle Indicators
Math Operators
Math Transform
Momentum Indicators
Overlap Studies
Pattern Recognition
Price Transform
Statistic Functions
Volatility Indicators
Volume Indicators

Stock Overview, Methodology & Data Sources

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California. Day One operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 94 people. Market structure and macro sensitivity help explain how Day One behaves across regimes. Price movements may be comparatively less responsive to macroeconomic volatility. Day One has a market cap of 2.2 B, P/E of 3.88, ROE of -22.74%.

Methodology

Unless otherwise specified, financial data for Day One Biopharmaceuticals is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Day (USA Stocks:DAWN) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: Information presented is compiled from public filings and market reference sources and official institutions such as U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO). Updates can be delayed depending on reporting conventions. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.

Analyst Sources

Day One Biopharmaceuticals is covered by 8 analysts. 4 analysts have submitted revenue and/or earnings estimates that may be incorporated into Macroaxis consensus inputs where available. Representative analyst firms may include Goldman Sachs, Jefferies, Bank of America Securities, Morgan Stanley, Barclays, Evercore ISI, Deutsche Bank, among others. Updates may occur throughout the day.

This content is curated and reviewed by:

Vlad Skutelnik - Macroaxis Contributor

Learn to be your own money manager

Tracking Day One inside a portfolio is useful because individual winners can still weaken diversification or distort overall risk targets. A disciplined tracking process turns performance data into better decisions instead of more noise.

Did you try this?

Run Portfolio Analyzer Now

   

Portfolio Analyzer

Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
All  Next Launch Module

Day One pair trading

Pair trading with Day One can help investors hedge some company-specific exposure by balancing a long view with an offsetting position. The key question is whether the second leg adds real hedge value instead of just creating a more complex version of the same risk.

Day One Pair Trading

Day One Biopharmaceuticals Pair Trading Analysis

Correlation analysis for Day One Biopharmaceuticals supports tax-loss harvesting by identifying similar assets that can temporarily replace Day One without violating wash-sale rules. Maintaining a high correlation to Day One Biopharmaceuticals during this period minimizes unintended changes to portfolio risk.
The correlation of Day One measures co-movement with other instruments on a scale from -1 to +1. Coefficients near +1 imply that paired assets move almost identically to Day One, while values near 0 indicate statistical independence and genuine diversification potential.
Pair evaluation and Correlation analysis for Day One provide hedging context. The method can be applied across sectors and broader equity sets.
Pair CorrelationCorrelation Matching

More Resources for Day Stock Analysis

A structured review of Day One often starts with core financial statements and trend context. Ratios and trend metrics help frame Day One's operating context. Selected reports below provide context for Day Stock:
How To Invest In Day
Details
Is Day Stock a good investment?
Details
What is Day One's Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Day One has a market cap of 2.2 B, operating margin of -51.12%, ROE of -22.74%. Investing Opportunities can help frame allocation decisions. The allocation includes a position in Day One Biopharmaceuticals within the allocation view. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.
Analysis related to Day One should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
 Earnings Share
-1.04
 Revenue Per Share
1.533
 Quarterly Revenue Growth
0.839
 Return On Assets
-0.15
 Return On Equity
-0.23
Market capitalization and book value offer complementary views of Day One — the first driven by investor sentiment, the second by accounting standards. Day One's market capitalization is 2.2 B. With a P/B ratio of 4.99, the market values Day One well above its book equity. Enterprise value stands at 1.76 B. Value and price for Day One are related but not identical, and they can diverge across cycles. Trading price represents the transaction level agreed by market participants.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Analysis
Details
Earnings
Projections
Details
Value and price for Day One are related but not identical, and they can diverge across cycles. For Day One, key inputs include a P/E ratio of 3.88, a P/B ratio of 4.99, a profit margin of -67.85%, and ROE of -22.74%. Market price reflects the current exchange level formed by active bids and offers.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY